Want to see NGNE full AI Analyst Report?
NGNE Stock Chart & Stats
$34.90
-$0.67(-1.88%)
At close: 4:00 PM EDT
$34.90
-$0.67(-1.88%)
Day’s Range― - ―
52-Week Range$15.93 - $43.66
Previous Close$34.9
Volume161.73K
Average Volume (3M)270.69K
Market Cap
$655.40M
Enterprise Value$371.51M
Total Cash (Recent Filing)$243.18M
Total Debt (Recent Filing)$9.13M
Price to Earnings (P/E)―
Beta3.10
Next Earnings
Aug 07, 2026EPS Estimate
-1.42Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.03
Shares Outstanding19,926,900
10 Day Avg. Volume213,349
30 Day Avg. Volume270,693
Financial Highlights & Ratios
PEG Ratio5.20
Price to Book (P/B)1.65
Price to Sales (P/S)0.00
P/FCF Ratio-5.57
Enterprise Value/Market Cap0.57
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-9.71
Enterprise Value/Ebitda-3.89
Forecast
1Y Price Target
$80.71Price Target Upside131.27% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)-5.51
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage / Solid Balance SheetA very low debt-to-equity (~0.04) and substantial equity provide durable financial flexibility for a pre-commercial biotech. This reduces bankruptcy risk, supports multi-year R&D funding capacity, and allows management to prioritize development decisions over near-term liquidity pressures.
Extended Cash Runway From Equity OfferingA completed equity and warrant financing providing roughly $135M extends runway into Q1 2029, materially lowering near-term financing risk. This structural funding allows completion of registrational activities and milestone-driven execution without immediate dependence on capital markets.
Durable Positive Clinical Signals For NGN-401Long-term Phase 1/2 data showing sustained multidomain functional gains through 30 months and favorable tolerability provide durable clinical de-risking. Persistent improvements versus natural history strengthen the registrational profile and support a viable path to approval and eventual commercial value.
Bears Say
High And Growing Cash BurnDeeply negative operating and free cash flows signal sustained cash consumption to advance programs. Persistently rising burn elevates reliance on external financing, constrains optionality for pipeline expansion, and increases the chance of dilutive capital raises if milestones slip.
Pre-commercial, Widening Net LossesThe company remains revenue-less with materially widening net losses, reflecting heavy investment without product cashflows. Over time this limits self-funding capacity, keeps returns negative, and makes long-term sustainability contingent on successful trials or continual external funding.
Dilution And Declining Equity BaseWhile the financing extends runway, it dilutes existing holders and follows an observable decline in equity, indicating reliance on issuance to fund operations. Repeated dilution can erode shareholder value and complicate long-term EPS accretion once/if commercial revenues arrive.
Neurogene News
NGNE FAQ
What was Neurogene Inc.’s price range in the past 12 months?
Neurogene Inc. lowest stock price was $15.93 and its highest was $43.66 in the past 12 months.
What is Neurogene Inc.’s market cap?
Neurogene Inc.’s market cap is $655.40M.
When is Neurogene Inc.’s upcoming earnings report date?
Neurogene Inc.’s upcoming earnings report date is Aug 07, 2026 which is in 4 days.
How were Neurogene Inc.’s earnings last quarter?
Neurogene Inc. released its earnings results on May 12, 2026. The company reported -$1.39 earnings per share for the quarter, missing the consensus estimate of -$1.296 by -$0.094.
Is Neurogene Inc. overvalued?
According to Wall Street analysts Neurogene Inc.’s price is currently Undervalued.
Does Neurogene Inc. pay dividends?
Neurogene Inc. does not currently pay dividends.
What is Neurogene Inc.’s EPS estimate?
Neurogene Inc.’s EPS estimate is -1.42.
How many shares outstanding does Neurogene Inc. have?
Neurogene Inc. has 19,926,900 shares outstanding.
What happened to Neurogene Inc.’s price movement after its last earnings report?
Neurogene Inc. reported an EPS of -$1.39 in its last earnings report, missing expectations of -$1.296. Following the earnings report the stock price went up 3.424%.
Which hedge fund is a major shareholder of Neurogene Inc.?
Currently, no hedge funds are holding shares in NGNE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Neurogene Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$80.71 (131.27% Upside)
$80.71 (131.27% Upside)
Blogger Sentiment
Bearish
NGNE Sentiment 100%
Sector Average 65%
Sector Average 65%
Crowd Wisdom
Very Negative
Last 7 Days ▼ 4.4%
Last 30 Days ▼ 2.0%
Last 30 Days ▼ 2.0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
52.37%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-16.54%
Trailing 12-Months
Company Description
Neurogene Inc.
Neurogene Inc. is dedicated to engineering transformative genetic treatments for individuals and their families grappling with debilitating neurological conditions. Its current pipeline prominently features two key investigational therapies: NGN-401, an AAV9 gene therapy specifically targeting Rett syndrome, and NGN-101, which is being developed to address neuronal ceroid lipofuscinosis subtype 5 (Batten disease). The company's operations are based in New York, New York.
NGNE Stock 12 Month Forecast
Average Price Target
$80.71
▲(131.27% Upside)
Technical Analysis
Silence Therapeutics
―
Atea Pharmaceuticals
―
Elicio Therapeutics
―
Vor Biopharma
―
Tenaya Therapeutics
―
Ownership Overview
7.38% Insiders
6.61% Mutual Funds
0.09% Other Institutional Investors
77.64% Public Companies and
Individual Investors